Latest News

World Hepatitis Day survey findings reveal gaps in chronic hepatitis B awareness and liver cancer risk perception, with Cary James discussing elimination efforts.

The FDA has officially granted Fast Track designation to HTX-001 for the treatment of non-obstructive hypertrophic cardiomyopathy.

Organon reports pooled phase 3 data showing tapinarof cream (VTAMA) improved atopic dermatitis severity across pediatric and adult age groups by Week 8.

The Voluntary Sodium Reduction Goals, issued in October 2021, resulted in no significant reduction in sodium content among packaged foods.

The first-in-class NDSRI showed significant symptom improvement as early as week 1 across 4 phase 3 trials but carries boxed warnings for suicidality and abuse potential.

Thanai Pongdee, MD, discusses how PIONEER data reveal quality of life gains that go beyond symptom and biomarker control in indolent systemic mastocytosis.

Walter Liszewski, MD, discusses how dermatologists can personalize atopic dermatitis treatment using biologics, JAK inhibitors, and topicals.

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged ≥45 years.

Abbas Zaidi, MD, discusses his recent study providing 5 pain points and 5 suggested improvements for the pediatric hypertension treatment flow.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia, the FDA approval of Furoscix ReadyFlow, and more.

Daniel Soteres, MD, discusses KONFIDENT-S data showing sebetralstat quickly resolves breakthrough HAE attacks in patients on long-term prophylaxis

Sanofi has discontinued development of OX40L-targeting amlitelimab for atopic dermatitis, following the heels of Kyowa Kirin's similar rocatinlimab discontinuation.

Jason Hawkes, MD, explains how new biologics and targeted therapies are advancing precision medicine and improving personalized care in atopic dermatitis.

The approval makes MannKind Corporation’s furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

Allergists explain what's settled about epinephrine nasal spray, what's not, and how to counsel patients before anaphylaxis guidelines catch up.

APPs discuss insurance barriers, dupilumab as the default COPD biologic, depemokimab adherence advantages, and why pulmonary rehab remains critically underused.

Pulmonologists weigh in on biologic selection, mepolizumab tachyphylaxis, COPD payer barriers, and why asthma outcomes far outpace COPD in real-world practice.

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

In this Q&A following EAC 2026, Blumenthal discusses perioperative anaphylaxis risk stratification, hidden OR triggers, and penicillin allergy de-labeling.

Hear Philip Adamson, MD, MSc, discuss his path through heart failure and his work with Abbott and CVRx.

Richard Lafayette, MD, discusses how atacicept's FDA approval advances BAFF/APRIL targeting in IgA nephropathy.

Ann Marie Navar, MD, PhD, highlights enlicitide’s FDA approval for hypercholesterolemia and its potential to fundamentally change therapy.

Monopar initiated a rolling NDA submission for ALXN1840, an investigational therapy for Wilson disease targeting copper dysregulation.